Cefoselis (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412530

CAS#: 122841-10-5 (free base)

Description: Cefoselis (free base) is a cephalosporin

Chemical Structure

img
Cefoselis (free base)
CAS# 122841-10-5 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 412530
Name: Cefoselis (free base)
CAS#: 122841-10-5 (free base)
Chemical Formula: C19H22N8O6S2
Exact Mass: 522.11
Molecular Weight: 522.560
Elemental Analysis: C, 43.67; H, 4.24; N, 21.44; O, 18.37; S, 12.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 122841-10-5 (free base)   122841-12-7 (sulfate)  

Synonym: Cefoselis (free base); UNII-0B50MLU3H1

IUPAC/Chemical Name: (6R,7R)-3-((5-amino-1-(2-hydroxyethyl)-1H-pyrazol-2-ium-2-yl)methyl)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key: BHXLLRXDAYEMPP-SBGRAJFYSA-N

InChi Code: InChI=1S/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H4,21,22,23,29,31,32)/b24-12-/t13-,17-/m1/s1

SMILES Code: CO/N=C(c1nc(N)sc1)\C(N[C@H]2[C@H]3SCC(C[n+]4n(CCO)c(N)cc4)=C(C([O-])=O)N3C2=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 522.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ohtaki K, Matsubara K, Fujimaru S, Shimizu K, Awaya T, Suno M, Chiba K, Hayase N, Shiono H. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. doi: 10.1007/s00702-004-0177-0. Epub 2004 Jul 7. PMID: 15565489.

2: Zalewski P, Skibiński R, Talaczyńska A, Paczkowska M, Garbacki P, Cielecka- Piontek J. Stability studies of cefoselis sulfate in the solid state. J Pharm Biomed Anal. 2015 Oct 10;114:222-6. doi: 10.1016/j.jpba.2015.05.033. Epub 2015 Jun 1. PMID: 26073113.

3: Liu YB, Lv XJ, Yu RJ, Qiu HM, Bai JL, Jiang N, Lin JM, Liu YJ, Yan HY, Song SD, He P, Guo DY, Li XS. Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections. Eur Rev Med Pharmacol Sci. 2014;18(14):2006-12. PMID: 25027339.

4: Yamazaki S, Mochizuki Y, Terai T, Sugimoto M, Uchida I, Matsuoka N, Mutoh S. Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. Pharmacol Biochem Behav. 2002 Dec;74(1):53-9. doi: 10.1016/s0091-3057(02)00947-4. PMID: 12376152.

5: Nagata M, Yasuhara M. Effect of experimental renal failure on the pharmacodynamics of cefoselis-induced seizures in rats. Biol Pharm Bull. 2001 Sep;24(9):1049-52. doi: 10.1248/bpb.24.1049. PMID: 11558567.

6: Sugimoto M, Fukami S, Kayakiri H, Yamazaki S, Matsuoka N, Uchida I, Mashimo T. The beta-lactam antibiotics, penicillin-G and cefoselis have different mechanisms and sites of action at GABA(A) receptors. Br J Pharmacol. 2002 Jan;135(2):427-32. doi: 10.1038/sj.bjp.0704496. PMID: 11815378; PMCID: PMC1573156.

7: Cheng JW, Su JR, Xiao M, Yu SY, Zhang G, Zhang JJ, Yang Y, Duan SM, Kudinha T, Yang QW, Xu YC. In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China. Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. PMID: 32184764; PMCID: PMC7058541.

8: Chimura T, Hirayama T, Morisaki N, Murayama K, Sato F, Akatsuka K, Numazaki M, Igarashi Y. [Clinical effects of cefoselis (CFSL) on infections in obstetric and gynecologic field and prevention of postoperative infections]. Jpn J Antibiot. 2000 Nov;53(11):637-41. Japanese. PMID: 11211699.

9: King A, Bethune L, Phillips I. The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect. 1995 Sep;1(1):13-17. doi: 10.1111/j.1469-0691.1995.tb00018.x. PMID: 11866715.

10: Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, Tympanidou C, Giamarellou H. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Diagn Microbiol Infect Dis. 2000 Mar;36(3):185-91. doi: 10.1016/s0732-8893(99)00131-5. PMID: 10729661.